Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study
| Autor: | Darren M. Moss, Andrew Owen, Rajith K. R. Rajoli, Anthony T. Podany, Marco Siccardi, Susan Swindells, Charles Flexner |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male 0301 basic medicine Pulmonary and Respiratory Medicine Physiologically based pharmacokinetic modelling Tuberculosis Adolescent 030106 microbiology Population Antitubercular Agents Pharmacology Injections Intramuscular Proof of Concept Study Drug Administration Schedule Young Adult 03 medical and health sciences chemistry.chemical_compound Pharmacokinetics Latent Tuberculosis Isoniazid medicine Humans Dosing Diarylquinolines education Oxazoles education.field_of_study business.industry Middle Aged medicine.disease Rifapentine Drug Liberation Treatment Outcome Infectious Diseases chemistry Nitroimidazoles Drug Therapy Combination Female Rifampin Bedaquiline Delamanid business medicine.drug |
| Zdroj: | INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE |
| ISSN: | 1027-3719 |
| DOI: | 10.5588/ijtld.17.0515 |
| Popis: | Setting Anti-tuberculosis formulations necessitate uninterrupted treatment to cure tuberculosis (TB), but are characterised by suboptimal adherence, which jeopardises therapeutic efficacy. Long-acting injectable (LAI) formulations or implants could address these associated issues. Objective niazid, rifapentine, bedaquiline and delamanid-in adults for treatment for latent tuberculous infection (LTBI). Design PBPK models were developed and qualified against available clinical data by integrating drug physicochemical properties and in vitro and population pharmacokinetic data into a mechanistic description of drug distribution. Combinations of optimal dose and release rates were simulated such that plasma concentrations were maintained over the epidemiological cut-off or minimum inhibitory concentration for the dosing interval. Results The PBPK model identified 1500 mg of delamanid and 250 mg of rifapentine as sufficient doses for monthly intramuscular administration, if a formulation or device can deliver the required release kinetics of 0.001-0.0025 h-1 and 0.0015-0.0025 h-1, respectively. Bedaquiline and isoniazid would require weekly to biweekly intramuscular dosing. Conclusion We identified the theoretical doses and release rates of LAI anti-tuberculosis formulations. Such a strategy could ease the problem of suboptimal adherence provided the associated technological complexities for LTBI treatment are addressed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|